Your browser doesn't support javascript.
loading
Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars.
Mosegui, Gabriela Bittencourt Gonzalez; Antõnanzas, Fernando; de Mello Vianna, Cid Manso; Rojas, Paula.
Afiliação
  • Mosegui GBG; Department of Health and Society, Community Health Institute, Fluminense Federal University, Rua: Marquês do Paraná, 303, 3° floor, annex building, Niterói, RJ, CEP: 24033-900, Brazil. gabrielamosegui@uol.com.br.
  • Antõnanzas F; Department of Economy and Company, Economy Faculty, University of La Rioja, Calle la Cigüeña, 60, 26006, Logroño, La Rioja, Spain.
  • de Mello Vianna CM; Department of Health Policy, Planning and Management, Health Medicine Institute, Rio de Janeiro Estadual University, Rua São Francisco Xavier 524 - Maracanã, Bloco D, 7° floor, Rio de Janeiro, RJ, 20550-013, Brazil.
  • Rojas P; Department of Economy and Company, Economy Faculty, University of La Rioja, Calle la Cigüeña, 60, 26006, Logroño, La Rioja, Spain.
Adv Rheumatol ; 61(1): 14, 2021 02 25.
Article em En | MEDLINE | ID: mdl-33632333
BACKGROUND: The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars. METHODS: We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies' databases. The pricing between countries was based on purchasing power parity (PPP). RESULTS: The US authorized the commercialization of 13 distinct biologicals and four biosimilars in the period. Spain and Brazil marketed 14 biopharmaceuticals for RA, ten original, four biosimilars. Colombia and Mexico have authorized three biosimilars in addition to the ten biological ones. For biological drug prices, the US is the most expensive country. Spain's price behavior seems intermediate when compared to the three LA countries. Brazil has the highest LA prices, followed by Mexico and Colombia, which has the lowest prices. Spain has the lowest values in PPP, compared to LA countries, while the US has the highest prices. CONCLUSION: The economic effort that LA countries make to access these medicines is much higher than the US and Spain. The use of the PPP ensured a better understanding of the actual access to these inputs in the countries analyzed.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Custos de Medicamentos / Medicamentos Biossimilares Tipo de estudo: Health_economic_evaluation Limite: Humans País/Região como assunto: America do sul / Brasil / Colombia / Europa / Mexico Idioma: En Revista: Adv Rheumatol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Custos de Medicamentos / Medicamentos Biossimilares Tipo de estudo: Health_economic_evaluation Limite: Humans País/Região como assunto: America do sul / Brasil / Colombia / Europa / Mexico Idioma: En Revista: Adv Rheumatol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido